|
Catalog #
|
Source:
|
Lot #
|
Size:
|
|
AP1809b
|
Rabbit
|
SH050705C
|
0.1 mg
|
|
Concentration:
|
Accession:
|
Clone Name:
|
Isotype:
|
|
0.25 mg/ml
|
NP_037457, Q9Y4P1
|
RB7558
|
Rabbit Ig
|
|
Applications:
|
Reactivity:
|
MW (kDa):
|
|
WB, IHC, E
|
H, M, B*
|
44309 Da
|
|
Target/Specificity:
|
|
This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide surrounding amino acid G93 of human APG4B.
|
|
Other Names:
|
|
APG4B, AUTL1, MGC1353, APG4 autophagy 4 homolog B; AUT-like 1 cysteine endopeptidase; autophagin-1; autophagy-related cysteine endopeptidase 1; autophagy-related protein 4 homolog B; cysteine protease ATG4B; hAPG4B
|
|
Application Data:
|
(LEFT) Western blot analysis of anti-hAPG4B-G93 Pab (Cat. #AP1809b) in 293 cell line lysates transiently transfected with the ATG4B gene (2ug/lane). hAPG4B-G93(arrow) was detected using the purified Pab (1:60 dilution).
(RIGHT) Western blot analysis of anti-APG4B Pab (Cat. #AP1809b) in mouse brain tissue lysate. APG4B(arrow) was detected using the purified Pab. |
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma. |
|
|
Background:
|
|
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole).
APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.
|
|
Background References:
|
- Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005)
- Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005)
- Greenberg JT. Dev Cell. 8(6):799-801. (2005)
- Levine B. Cell. 120(2):159-62. (2005)
- Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)
|
|
Product Citations:
|
|
|
|
Application Notes:
|
| The suggested dilution is: | |
| ELISA | 1:1,000 |
| Western blotting | 1:100~500 |
| Immunohistochemistry | 1:50~100 |
|
|
Format:
|
|
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
|
|
Storage:
|
|
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
|
|
Precautions:
|
|
This product is for research use only. Not for use in diagnostic
or therapeutic procedures.
|
